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Tobacco smokeChronic obstructive pulmonary disease (COPD) is an incurable global health burden and is characterised by pro-
gressive airﬂow limitation and loss of lung function. In addition to the pulmonary impact of the disease, COPD
patients often develop comorbid diseases such as cardiovascular disease, skeletal muscle wasting, lung cancer
and osteoporosis. One key feature of COPD, yet often underappreciated, is the contribution of oxidative stress
in the onset and development of the disease. Patients experience an increased burden of oxidative stress due
to the combined effects of excess reactive oxygen species (ROS) and nitrogen species (RNS) generation, antiox-
idant depletion and reduced antioxidant enzyme activity. Currently, there is a lack of effective treatments for
COPD, and an even greater lack of research regarding interventions that treat both COPD and its comorbidities.
Due to the involvement of oxidative stress in the pathogenesis of COPD and many of its comorbidities, a unique
therapeutic opportunity arises where the treatment of a multitude of diseases may be possible with only one
therapeutic target. In this review, oxidative stress and the roles of ROS/RNS in the context of COPD and comorbid
cardiovascular disease, skeletal musclewasting, lung cancer, and osteoporosis are discussed and the potential for
therapeutic beneﬁt of anti-oxidative treatment in these conditions is outlined. Because of the unique interplay
between oxidative stress and these diseases, oxidative stress represents a novel target for the treatment of
COPD and its comorbidities.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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An increased burden of oxidative stress is an important feature of the
pathogenesis of chronic obstructive pulmonary disease (COPD) and its
associated comorbid diseases (comorbidities). Current forms of therapy
for COPD are largely ineffective and the development of effective treat-
ments for COPD has been severely hampered as the mechanisms and
mediators that drive the induction and progression of chronic inﬂamma-
tion, emphysema, altered lung function, defective lung immunity and
many extrapulmonary comorbidities are still poorly understood. What
is known is that four primary mechanisms have been implicated in the
pathophysiological alterations observed in COPD: oxidative stress; in-
ﬂammation; protease–antiprotease imbalance; and apoptosis (Barnes,
2013, 2014; Hillas, Nikolakopoulou, Hussain, & Vassilakopoulos, 2013).
Althoughmostly underappreciated, oxidative stress has been recognized
as a central component in the pathogenesis of COPD as it can trigger and
further potentiate the other three mechanisms. In this review we focus
on the role of oxidative stress in the pathogenesis of COPD and its comor-
bidities. Given its pivotal role in the onset and development of COPD, ox-
idative stress may be a novel target for the treatment of COPD and its
comorbidities.
1.1. Chronic obstructive pulmonary disease overview
COPD represents an increasing global burden, afﬂicting over 600
million people and corresponding to approximately 5% of all deaths
globally (Koul, 2013). It is currently the third leading cause of death
(Lozano et al., 2012). It is well known that lower/middle income coun-
tries bear most of the burden of COPDwith almost 90% of COPD-related
deaths worldwide taking place in these countries (Lopez et al., 2006).
Although the incidence rate of COPD is likely to escalate in both devel-
oped and developing countries, COPD poses a heavier burden on the
Asia-Paciﬁc and African regions where smoking is still widespread and
gradually increasing (Chan-Yeung, Ait-Khaled, White, Ip, & Tan, 2004;
Adeloye et al., 2015). Cigarette smoke is inarguably the biggest risk fac-
tor for COPD, with 90% of deaths from COPD directly attributable to
smoking (Tashkin & Murray, 2009). Other risk factors include exposure
to air pollutants and biomass fuels (Song, Christiani, XiaorongWang, &
Ren, 2014). In addition, there is generally a long latency period between
exposure to smoke and clinically-evident disease and as such, there is a
high incidence of COPD in the older population and ex-smokers
(Theander et al., 2014). This latency period generally lasts a number of
years and by the time patients become symptomatic, the damage is al-
ready irreversible.
COPD is characterized by persistent airﬂow limitation and lung
inﬂammation resulting in a progressive decline in lung function
(Angelis et al., 2014). The main symptoms of the disease are chronic
cough (smoker's cough), excessive mucus production and dyspnoea
(particularly during exercise) (Theander et al., 2014). In addition to the
pulmonary manifestation of COPD, many systemic manifestations occur
in the formof comorbid diseases, such as skeletalmusclewasting, cardiac
dysfunction, osteoporosis and lung cancer (Chatila, Thomashow, Minai,
Criner, & Make, 2008; Barnes & Celli, 2009; Patel & Hurst, 2011). These
comorbidities have been associated with increased oxidative stress and
are known to affect, or are strong predictors of, themortality of COPD pa-
tients independent of the decline in lung function (Schols, Slangen,
Volovics, & Wouters, 1998; Marquis et al., 2002; Sin, Anthonisen,
Soriano, & Agusti, 2006; Swallow et al., 2007).
Although COPD is a largely preventable disease; the numbers of di-
agnoses continue to increase resulting in ever increasing medical costs
to patients, communities and governments (Lozano et al., 2012; GOLD,
2015). COPD patients generally have long hospital stays, require long-
term treatments, and in addition to these medical costs, other “costs”
such as an increase in days missed fromwork and limitations to quality
of life, are important consequences of this disease (Rabe, 2007; Vestbo
et al., 2013).1.2. Acute exacerbations of chronic obstructive pulmonary disease
Patients with COPD often experience episodes of sudden worsening
of symptoms, known as acute exacerbations (AECOPD). The Global ini-
tiative for chronic Obstructive Lung Disease (GOLD) deﬁnes an exacer-
bation as “a change in the patient's baseline dyspnoea, cough, and/or
sputum and beyond normal day-to-day variations, that is acute in
onset and may warrant a change in regular medication in a patient
with underlying COPD”. These exacerbations are considered to be part
of the natural progression and chronicity of the disease and as COPD
progresses, exacerbations become increasingly more frequent (Hurst
& Wedzicha, 2009; Mackay & Hurst, 2013). Exacerbations result in a
dramatic increase in lung inﬂammation and are associated with in-
creased systemic inﬂammation compared to stable disease and as a re-
sult, there is only an increase in oxidative stress markers (Stanojkovic
et al., 2011). This contributes to the worsening of symptoms and it has
been shown that followinghospitalisation for AECOPD, patients have in-
creased mortality rates (Steer, Gibson, & Bourke, 2010).
AECOPD is often triggered by respiratory infections, such as those
caused by the bacteria Streptococcus pneumoniae and Inﬂuenza A virus,
or acute exposure to airborne irritants (Repine, Bast, & Lankhorst,
1997; Mackay & Hurst, 2013). There are also many non-aetiological
risk factors that contribute to the frequency of exacerbations such
as age, frequent past exacerbations and the presence of comorbid
diseases (especially cardiovascular disease) (Laratta & van Eeden,
2014). The rates of exacerbations vary dramatically depending on
the parameters used to deﬁne an exacerbation, however, rates of se-
vere AECOPD measured by hospitalisations occur at an approximate
rate of 0.5 to 3.6/person-year depending on the study cited (de Melo,
Ernst, & Suissa, 2004; Seemungal, Hurst, &Wedzicha, 2009). The out-
comes of AECOPD can vary from the return to near baseline spiro-
metric parameters to respiratory failure and death. Exacerbations
are the largest direct cost for the treatment of COPD due to the length
of hospital stays and the frequency of the exacerbations per patient
(Miravitlles, Murio, Guerrero, Gisbert, & EPOC, 2002; Miravitlles
et al., 2004; Mackay & Hurst, 2013).2. Oxidative stress in chronic obstructive pulmonary disease
2.1. What is oxidative stress?
Oxidative stress refers to the imbalance between the oxidant and an-
tioxidant levels in favour of a pro-oxidant environment in cells and tis-
sues (Kalyanaraman, 2013). An oxidant is a species that causes or
promotes oxidation and an antioxidant is amolecule that inhibits either
the formation of oxidants or inhibits oxidation itself. Oxidative stress
arises from the inability of innate antioxidant mechanisms to neutralize
oxidants generated endo- or exogenously resulting in an imbalance be-
tween oxidant and antioxidant factors. Consequentially, the oxidants
predominate and chronic oxidative stress occurs, leading to themodiﬁ-
cation of lipids, proteins, and DNA (Rahman, 2005; Biswas, Hwang,
Kirkham, & Rahman, 2013). The harmfulmodiﬁcations caused by oxida-
tive stress are referred to as oxidative damage.
Oxidative stress can result from increased production of oxidants (in
the form of free radicals/reactive oxygen and nitrogen species) or from
diminished antioxidant levels or reduced antioxidant enzyme activity
(Kalyanaraman, 2013). The depletion of dietary antioxidants
(e.g., vitamins E, C, andD,ﬂavonoids and carotenoids) andmicronutrients
(e.g., iron, copper, zinc, selenium) can also contribute to oxidative stress
as they are needed for proper functioning of antioxidant enzymes
(Delles, Xiong, True, Ao, &Dawson, 2014). In chronic inﬂammatory condi-
tions, such as COPD, oxidative stress primarily results from the increased
production of reactive oxygen species (ROS) fromexposure to toxins (e.g.,
cigarette smoke, infection) and continuous activation of endogenous en-
zymes (e.g., NADPH oxidases) (Fig. 1).
Fig. 1.Overview of oxidative stress in the pathogenesis of COPD. The generation of reactive oxidant species both exogenously and endogenously can lead to the onset and development of
COPD and its comorbidities. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are found in cigarette smoke but in COPD the primary sources of ROS and RNS are from
inﬂammatory cells includingmacrophages, neutrophils and epithelial cells.When activated by inhaled irritants (e.g., cigarette smoke), enzymatic (e.g., NADPH oxidase) generation of ox-
idants leads to the depletion of scavenging antioxidants (e.g., vitamin E), resulting in oxidative stress.
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The prolonged increase in oxidative stress is a major factor in poten-
tiating both the airway and systemic inﬂammation in COPD and is
known to play a key role in the onset and development of COPD and
its comorbidities (Montuschi et al., 2000; Cavailles et al., 2013;
Kirkham & Barnes, 2013). Direct damage occurs due to the oxidants
found in cigarette smoke and from excessive levels of ROS and reactive
nitrogen species (RNS) produced as a result of both pulmonary and sys-
temic inﬂammation. An increase in ROS production in the airways is
reﬂected by elevated levels of markers of oxidative stress (e.g., superox-
ide and malondialdehyde) in the airspaces, sputum, breath, lungs, and
blood in patients with COPD (Rahman, 2005; Stanojkovic et al., 2011).
These levels of oxidative stress markers are also dramatically increased
during exacerbations of COPD (Antus, Harnasi, Drozdovszky, & Barta,
2014). Due to the nature of the oxidative burden and its consequences
in the progression of COPD, this review is primarily focused on the
role of ROS/RNS in the pathogenesis of COPD and its comorbidities,
and the potential pharmacological targets related to ROS signalling.2.1.2. Environmentally-derived reactive oxygen species
Eachpuff of cigarette smoke containsmore than 1015–17 oxidant/free
radical molecules and over 4700 highly reactive chemical compounds,
such as aldehydes and quinones, which increases the oxidant burden
in smokers (Church & Pryor, 1985; Nakayama, Church, & Pryor, 1989;
Pryor & Stone, 1993; Rahman, 2005, 2012; Kirkham & Barnes, 2013).
The nature of ROS found within cigarette smoke varies from short-
lived oxidants, such as the superoxide radical (O2•−) and the nitric
oxide radical (NO•), to long-lived organic radicals, such as semiquinones
that can undergo redox cycling within the epithelial lining ﬂuid of
smokers for some considerable period of time (Nakayama et al., 1989;Valavanidis, Vlachogianni, & Fiotakis, 2009a,2009b). Lung and systemic
formation of protein carbonyls in response to cigarette smoke-derived
lipid peroxides/carbonyls have also been implicated in the pathogenesis
of COPD (Montuschi et al., 2000).
In addition to the release of oxidants, cigarette smoking is also asso-
ciated with an increased amount of myeloperoxidase (MPO) in neutro-
phils, an oxidising factor that forms hypochlorous acid and converts
tyrosine to tyrosyl radical (Bridges, Fu, & Rehm, 1985). Studies have
shown a correlation between the content of MPO in neutrophils and
the degree of pulmonary dysfunction observed in patients (Vaguliene,
Zemaitis, Lavinskiene, Miliauskas, & Sakalauskas, 2013). In addition,
studies suggest that neutrophil MPO-mediated oxidative stress plays a
role in lung inﬂammation (Gernez, Tirouvanziam, & Chanez, 2010). It
is also known that cigarette smoke can cause the activation of alveolar
macrophages, which is observed in the bronchoalveolar lavage ﬂuid
(BALF) from the lungs of smokers and COPD patients but not present
in non-smokers. The activation of macrophages contributes to the en-
dogenous generation of ROS in the respiratory tract (Kirkham,
Spooner, Ffoulkes-Jones, & Calvez, 2003; Barnes, 2004).
2.1.3. Cellular derived reactive oxygen species
Cellular-derived ROS is enzymatically produced by inﬂammatory
and epithelial cells within the lung and/or systemically as part of an
inﬂammatory-immune response towards a pathogen or irritant (Kim
et al., 2013). Production of ROS by phagocytes can be enhanced by oxi-
dants present in cigarette smoke leading to the release of inﬂammatory
mediators (Rahman, 2012). Several sources for ROS production exist
within a cell; however, the primary ROS generator is the enzyme
NADPH oxidase (NOX), which comes in various isoforms: NOX-1,
NOX-2, and NOX-4 (Selemidis, Sobey, Wingler, Schmidt, &
Drummond, 2008; Drummond, Selemidis, Griendling, & Sobey, 2011).
Fig. 3.The reactive nitrogen species cascade. In addition to its ability to cause direct damage,
ONOO− can also reactwith carbon dioxide (CO2) in vivo. The reaction betweenONOO− and
CO2 occurs rapidly under physiological conditions, forming nitrosoperoxycarbonate
(ONOOCO2−). ONOOCO2− homolyzes (the molecule dissociates into 2 free radicals) to form
the carbonate radical (•CO32−) and nitrogen dioxide (•NO2) (Kalyanaraman, 2013). It is
these radicals (•CO32− and •NO2) that are believed to cause peroxynitrite-related cellular
damage. The conjugate acid of peroxynitrite, peroxynitrous acid (HNO3) also homolyzes
into •OH and •NO2 radicals, adding to the oxidative burden caused by peroxynitrite
(Merenyi, Lind, Goldstein, & Czapski, 1998).
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made up of an enzyme complex which is present in phagocytic and
non-phagocytic cells including epithelial cells, macrophages, and skele-
tal muscles (Grifﬁth et al., 2009; Barbieri & Sestili, 2012). Although NOX
is found in many cell types, it is latent in neutrophils under normal cir-
cumstances (MacNee&Rahman, 2001). Once activated, neutrophils and
macrophages can generate ROS via the NADPH oxidase system, leading
to further augmentation of oxidative stress in the lungs of smokers and
COPD patients (Fig. 2).
NOX-generated ROS have long been recognized to play key roles in
the pathogenesis of a number of diverse chronic lung disorders that re-
sult in obstructive physiology, in particular asthma, cystic ﬁbrosis, and
emphysema (Grifﬁth et al., 2009). Mice deﬁcient in p47phox or NOX-2
exhibit increased cigarette smoke-induced lung inﬂammation and em-
physema despite decreased ROS production compared with control
mice (Yao et al., 2008). The lung responses in p47phox- and NOX2-null
mice were associated with increased production of pro-inﬂammatory
cytokines and chemokines via a TLR4–NF-kB pathway, indicating that
NOX-2maymediate anti-inﬂammatory functions by restraining TLR4 ac-
tivation (Yao et al., 2008). However, another group reported that
p47phox-null mice have less inﬂammation, IL-6, keratinocyte-derived
chemokine, and monocyte chemoattractant protein-1 in lung-lavage
specimens after cigarette-smoke exposure compared with WT mice
(Gicquel et al., 2008). The differences observed by these groups may be
due to variability in lung compartment sampling, cellular distributions,
and chronicity of cigarette-smoke exposure.
2.1.4. Reactive nitrogen species
Although increased production of ROS is the primary mechanism of
oxidative stress in COPD/chronic lung diseases/acute lung diseases,
there is compelling evidence to suggest that RNS also play a role in
COPD (Ichinose, Sugiura, Yamagata, Koarai, & Shirato, 2000; Ichinose
et al., 2003). Reactive nitrogen species include nitric oxide (NO•), a ni-
trogen free radical, and its derivative species such as peroxynitrite and
nitrogen dioxide (Fig. 3). As with ROS, in addition to generationFig. 2. Cellular generation of reactive oxygen and nitrogen species in COPD. Cigarette smoke a
activation of NADPH oxidase 2 (Nox2) generates superoxide radicals. (O2•−) which can then e
or be rapidly converted to hydrogen peroxide (H2O2) via the enzymatic activity of superoxide
hydroxyl radical (•OH) via the Fenton reaction. This reaction causes the oxidation of Fe2+ to Fe
These iron reactions have increased importance in COPD as a higher concentration of iron h
(Gloire et al., 2006). The glutathione peroxidase (Gpx) family of enzymes, and catalase (CAT) ar
reduces circulating ROS and thus reduces the oxidative burden (Vlahos & Bozinovski, 2013).endogenously, RNS are present in cigarette smoke and air pollutants
in the form of NO• and has many of the same harmful effects as ROS
(Hasnis, Bar-Shai, Burbea, & Reznick, 2007). Endogenously, NO• is asso-
ciated with a multitude of signalling pathways in mammalian physio-
logical and pathological processes; however, in excess it too causescts on inﬂammatory cells in the lung (e.g., macrophages, neutrophils, epithelium) where
ither react with nitric oxide (NO•) to form the reactive peroxynitrite molecule (ONOO−)
dismutase (SOD). In the presence of Fe2+, H2O2 can be converted into the more damaging
3+, and in this oxidation state, the presence of iron can directly generate •OH from O2•−.
as been reported in the lungs of smokers, thereby increasing the potential ROS burden
e responsible for the conversion of H2O2 into harmlesswater and oxygen, which effectively
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forming the even more harmful peroxynitrite radical (ONOO−).
2.1.4.1. Nitric oxide. For years, NO• had only been considered as a toxic,
unstable free radical gas that was just a constituent of air pollutant and
cigarette smoke.However, it is nowknown thatNO• can be generated en-
dogenously in several types of cells (Bredt, 1999). This implicated NO• in
various physiological roles and pathways, including host defence, vascu-
lar regulation and neuronal communication (Kalyanaraman, 2013). NO•
has been well characterized in human biology and is perhaps the most
important endogenous vasoprotective molecule in addition to its role in
cardiovascular function (Moncada & Higgs, 2006; Tang & Vanhoutte,
2009; Vanhoutte, Shimokawa, Tang, & Feletou, 2009; Feletou, Kohler, &
Vanhoutte, 2012). NO• inhibits vascular smooth muscle contraction and
growth, platelet aggregation, and leukocyte adhesion to the endothelium,
contributing to vascular homeostasis (Cooke, 2004; Moncada & Higgs,
2006; Tang & Vanhoutte, 2009; Vanhoutte et al., 2009; Feletou et al.,
2012; Triggle et al., 2012). Individuals with hypertension, atherosclerosis
and/or diabetes often show impaired NO• signalling, highlighting the im-
portance of NO•with regards to comorbid cardiovascular disease (Huang,
2009) (see below).
Nitric oxide is generated by phagocytes and is biosynthesized endog-
enously from the amino acid L-arginine, oxygen, and NADPH by various
nitric oxide synthase (NOS) enzymes (Palmer, Ashton, & Moncada,
1988). In addition to its signalling roles, NO• has both pro-oxidant and
antioxidant activities; excessive NO• can cause direct oxidative damage,
however, NO• can also scavenge circulating ROS (Joshi, Ponthier, &
Lancaster, 1999;Wink et al., 2001). More importantly, O2•− can react di-
rectly with endothelium-derived NO• forming the harmful ONOO−
molecule.
2.1.4.2. Peroxynitrite. Peroxynitrite is formed by the reaction between
O2•− and NO• in vivo. The pairing of these 2 radicals results in ONOO−
anion, which is not a free radical but is still a very potent oxidant.
ONOO− is both an oxidising and nitrating agent and can thus damage
a wide array of molecules, including DNA and proteins (Beckman,
1996; Szabo &Ohshima, 1997). The formation of ONOO− is of particular
relevance to the comorbidities of COPD as its formation involves the
consumption of NO•, reducing the bioavailability of NO• for physiologi-
cal processes (see Section 3.2.3).
2.1.5. Depletion of antioxidants
ROS/RNS generated exogenously or endogenously, whether circulat-
ing or in pulmonary vasculature, are scavenged by blood antioxidants
and antioxidant enzymes. Accordingly, the ability to protect against the
deleterious effects of oxidative stress depends greatly on the antioxidant
capacity of the blood and the tissues (Rahman, Morrison, Donaldson, &
MacNee, 1996; Rahal et al., 2014). Studies have shown that in addition
to the increased levels of circulating oxidants, there is also an observed
decrease in systemic antioxidant capacity in smokers and patients with
COPD (Rahman, Swarska, Henry, Stolk, & MacNee, 2000). This is due to
the saturation of lung antioxidants, plasma antioxidants and protein sulf-
hydryls by the excessive amounts of circulating ROS released by neutro-
phils and macrophages (Rahman et al., 2000). The saturation of many of
these antioxidants, such as uric acid, glutathione (GSH), vitamin E, and
ascorbate is also associated with the severity of COPD exacerbations
(Rahman, Skwarska, & MacNee, 1997). Cigarette smoke, the main
aetiological risk factor for COPD, has also been shown to irreversibly
modify glutathione to glutathione conjugates in the airway epithelium
resulting in antioxidant deﬁciency and injurious lung response (van
der Toorn et al., 2007). Cigarette smoking also inhibits the protective ex-
pression of the Nrf2/antioxidant response element pathway in peripher-
al mononuclear cells of smokers, favouring a pro-inﬂammatory state
(Garbin et al., 2009). In addition to the antioxidant saturation, studies
have also shown a decrease in anti-oxidative enzyme function in COPDpatients; speciﬁcally reduced SOD and Gpx activity (Kurys, Kurys,
Kuzniar, & Kieszko, 2001).
There is evidence to suggest that the anti-oxidant enzyme glutathi-
one peroxidase-1 (Gpx-1) may have a role in regulating the inﬂamma-
tory response to cigarette smoke exposure. Elevated levels of H2O2 are
measured in the exhaled breath condensate of COPD patients, particu-
larly during exacerbations (Dekhuijzen et al., 1996). There is upregula-
tion of Gpx-1 gene expression in the lungs of smokers (Bentley,
Emrani, & Cassano, 2008) and depletion of Gpx activity in COPDpatients
and smokers (Santos et al., 2004; Kluchova, Petrasova, Joppa, Dorkova, &
Tkacova, 2007; Vibhuti, Arif, Deepak, Singh, & Qadar Pasha, 2007).With
respect to reduced Gpx activity in COPD patients and smokers, erythro-
cyte Gpx activity was signiﬁcantly lower in patients with severe COPD
compared with patients with moderate COPD and there is a direct rela-
tionship between systemic Gpx activity and FEV1 (Kluchova et al.,
2007). In addition, Gpx activity was decreased in plasma from COPD pa-
tients and oxidative stress correlates with both lung function and body
mass index in COPD (Vibhuti et al., 2007). Moreover, Gpx activity was
decreased in total blood from smokers and ex-smokers (Santos et al.,
2004). However, these studies did not identify the isoform of Gpx that
was involved in reduced activity of Gpx.
2.2. Oxidative modiﬁcations
Oxidative stress causes a wide array of physiological and pathologi-
cal consequences not necessarily limited to just COPD patients. In COPD,
increased oxidative stress can cause cell damage, cell necrosis, apopto-
sis, autophagy, remodelling of extracellular matrix and blood vessels,
endothelial dysfunction, inactivation of antiproteases, premature cellu-
lar senescence, elevated mucus secretion, steroid resistance, unfolded
protein response, cell proliferation, epigenetic changes, and autoimmu-
nity (Rahman, 2005; Rahman & Kinnula, 2012; Kirkham & Barnes,
2013). Oxidativemodiﬁcations of DNA, proteins and lipids all contribute
to the pathophysiology of the disease.
2.2.1. DNA
Unlike the other ROS and RNSwhich do not react with DNA bases or
deoxyribose, the hydroxyl radical and peroxynitrite can react with both
purine (adenine & guanine) and pyrimidine (cytosine & thymine),
forming speciﬁc products (Cooke, Evans, Dizdaroglu, & Lunec, 2003).
This oxidative damage can lead to mutation of DNA bases caused by
AT–GC transition and GC-AT transversion and, if left unrepaired, can re-
sult in changes in protein gene expression (Kalyanaraman, 2013). In ad-
dition to this, ROS/RNS-induced DNA damage also involves single- or
double-stranded DNA breaks and DNA cross-links, DNA damage induc-
ing either arrest or induction of transcription, induction of signal trans-
duction pathways, replication errors, and genomic instability (Naito,
Suematsu, & Yoshikawa, 2011).
2.2.2. Protein
Oxidative modiﬁcations to proteins caused by ROS/RNS include pro-
tein fragmentation, oxidation of amino acids, the formation of car-
bonyls, dityrosine and nitrated and chlorinated tyrosines (Berlett &
Stadtman, 1997; Grimsrud, Xie, Grifﬁn, & Bernlohr, 2008). In COPD
and other inﬂammatory diseases, elevated levels of nitrated, chlorinated
and brominated tyrosines have been detected in the tissues of patients
(Kim, Mofarrahi & Hussain, 2008). These oxidative changes to proteins
can result in various functional consequences, such as inhibition of en-
zymatic and binding activities, increased susceptibility to aggregation
and proteolysis, modiﬁcations in uptake by cells, and altered immuno-
genicity (Shacter, 2000).
2.2.3. Lipids
In the presence of ROS/RNS and oxygen, lipids undergo a chain oxi-
dation reaction leading to peroxidation. This chain reaction is initiated
by oxidants, primarily the hydroxyl radical and leads to the formation
Fig. 4.Oxidants (•OH) abstract the allylic hydrogen from lipid molecules (LH) forming the
carbon-centred lipid radical. This radical then undergoes molecular rearrangement to
form a more stable form of the carbon-centred radical (L•). In the presence of oxygen, L•
rapidly forms a lipid peroxy radical (LOO•). This new radical can then abstract an allylic hy-
drogen from another lipid molecule generating a new L•. This process can be terminated
by the donation of a hydrogen atom from vitamin E to the LOO• species forming a vitamin
E radical. The vitamin E radical then reacts with another LOO• forming non-radical prod-
ucts and thus terminating the reaction.
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tion. This process continues indeﬁnitely unless terminated by phenolic
antioxidants, also known as chain-breaking antioxidants (e.g., vitamin
E) (Kalyanaraman, 2013) (Fig. 4). This is especially important in comor-
bid cardiovascular disease where the formation of plaques in the arter-
ies is initiated from lipid peroxidation.
2.3. Effects of oxidative stress
ROS and RNS normally play roles in cell signalling and homeostasis;
however, in excess they become increasingly toxic. The ROS and RNS
O2•−, ONOO−, H2O2 and •OH, in addition to their indiscriminate
oxidization of proteins, lipids and DNA (Taraseviciene-Stewart &
Voelkel, 2012), can result in direct lungdamage or induce an assortment
of cellular responses. Additionally, these oxidants also inﬂuence the in-
ﬂammatory responses in the lungs via various pathways such as the ac-
tivation of transcription factor NF-κB, and transcription of pro-
inﬂammatory mediator genes, further potentiating the inﬂammatory
response in COPD (Gloire, Legrand-Poels, & Piette, 2006). This induces
a pro-inﬂammatory state that drives the sustained production of more
ROS, leading to a vicious cycle of oxidative stress and inﬂammation.
The oxidative damage and modiﬁcations caused by ROS are known to
precede the characteristic respiratory changes seen in COPD such as air-
way remodelling and emphysema (Barreiro et al., 2010). Recent studieshave also shown a decrease in glucocorticosteroid receptor expression
as a result of prolonged oxidative stress indicating that in a pro-
oxidant environment, such as in COPD patients, steroid therapy is of
limited therapeutic beneﬁt highlighting the need for new treatments
(van Eeden & Sin, 2013).2.3.1. Systemic oxidative stress
Even after smoke cessation, systemic oxidative stress still persists in
COPD patients. This is reﬂected by an elevation in circulating ROS and a
depletion of antioxidants. The increased oxidative stress is likely due to
the persistent low grade systemic inﬂammation resulting in the produc-
tion of ROS systemically (Foschino Barbaro, Carpagnano, Spanevello,
Cagnazzo, & Barnes, 2007). This systemic oxidative stress has been im-
plicated in various systemic manifestations of COPD, with many studies
associating this increased burden of oxidative stress with skeletal mus-
cle wasting and cardiovascular disease in COPD (Foschino Barbaro et al.,
2007; Dalal, Shah, Lunacsek, & Hanania, 2011; Zampetaki, Dudek, &
Mayr, 2013). In addition to the links between oxidative stress in COPD
and comorbid diseases, increased extrapulmonary oxidative stress is
also an independent risk factor of many comorbidities such as cardio-
vascular disease, osteoporosis and depressive disorders in patients
without COPD (Sanchez-Rodriguez, Ruiz-Ramos, Correa-Munoz, &
Mendoza-Nunez, 2007; Kawada, 2012; Michel, Pulschen, & Thome,
2012).2.4. Oxidative stress in comorbidities
of chronic obstructive pulmonary disease
A prominent feature of COPD is the presence of comorbid diseases
(or comorbidities) in patients (Chatila et al., 2008; Patel & Hurst,
2011). These diseases can range frommore “mild” conditions that affect
quality of life such as osteoporosis anddepression, tomore fatal diseases
such as ischaemic heart disease and cancer. COPD-related mortality is
likely underestimated due to these comorbidities as their presence
makes it difﬁcult to determine the precise cause of death. Respiratory
failure is considered to be the major cause of death in advanced COPD;
however, comorbidities such as cardiovascular disease and lung cancer
are also major causes of death. In early/mid stages of COPD, comorbidi-
ties are the leading causes ofmortality (Sin et al., 2006). Comprehensive
studies on the speciﬁc cause of deaths in COPD patients have found that
rather than dying from progressive respiratory failure, many COPD pa-
tients die from a complex web of interconnected comorbidities (van
Eeden& Sin, 2013). For the purpose of this review, comorbidities are de-
ﬁned as the presence of one or more distinct diseases or disorders that
are not directly related to COPD or are not part of the natural history/
progression of the disease (e.g., respiratory infections resulting in
AECOPD). The underlyingmechanisms resulting in these systemicman-
ifestations in COPD are not fully understood; however, they have been
linked to the persistent low-grade systemic inﬂammation and persis-
tent oxidative stress in COPD as discussed earlier.3. Cardiovascular disease (CVD)
3.1. Cardiovascular disease overview
CVD is a broad term used to describe any disease involving the heart
and/or blood vessels. The presence of CVD is very common in COPD pa-
tients and is the leading cause ofmorbidity andmortality in younger pa-
tients and patients with mild-to-moderate COPD (Sin et al., 2006).
Comorbid CVD can manifest itself in one or more various disorders
such as angina, stroke, arrhythmias, hypertrophy of the heart, andmyo-
cardial infarction, and its presence greatly reduces the survivability of
COPD patients (Dalal et al., 2011).
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chronic obstructive pulmonary disease links
It is well documented that COPD and CVD share many of the same
risk factors, such as smoking, diet, and pre-existing hypertension.
When considering these risk factors it is of signiﬁcance that many, if
not all, contribute to disease progression at least in part via oxidative
stress. Multiple studies have shown links between COPD and classical
cardiovascular risk factors such as family history of coronary heart dis-
ease and diabetes (Sidney et al., 2005; Bursi, Vassallo, Weston, Killian,
& Roger, 2010; Terzano et al., 2010; Ford et al., 2012). Persistent low-
grade systemic inﬂammation is present in both COPD and CVD and ox-
idative stress, which plays a major role in COPD, has also been implicat-
ed in CVD (Zampetaki et al., 2013). This indicates that the systemic
inﬂammation and increased oxidative stress in COPD may lead to the
onset and development of comorbid CVD.
In addition to this, acute inﬂammatory lung conditions, such as bac-
terial/viral infection or acute exposure to airborne irritants, are also as-
sociated with vascular dysfunction (Mills et al., 2005, 2007). Increased
systemic inﬂammation, as a result of these lung conditions, is capable
of destabilizing vulnerable plaques, inducing a prothrombotic state
(Man, Van Eeden & Sin, 2012). COPD patients generally do not tolerate
cardiac injury or intervention as well as healthy individuals. COPD pa-
tients with acute myocardial infarction have a ﬁve-year survival rate
of 46% compared to 68% in those without COPD (Bursi et al., 2010).
3.1.2. Cardiovascular disease and acute
exacerbations of chronic obstructive pulmonary disease
Although many factors have been associated with poor outcomes
fromAECOPD, CVD is becoming increasingly recognized as a strong pre-
dictor of in-hospital mortality. Studies have shown that over 50% of pa-
tients hospitalized for AECOPD have a high prevalence of coexisting
cardiovascular disease (Stefanelli et al., 2013). Comorbid cardiovascular
disease is independently associated with increased risk of AECOPD
(Masunaga et al., 2003). The severity of airway obstruction is a major
predictor of AECOPD, and is also an independent risk factor for cardio-
vascular disease (Roberts et al., 2002; Mannino & Davis, 2006; Steer
et al., 2010; Mannino, 2011). There is also mounting evidence associat-
ing a high frequency of acute CVDwith acute respiratory illness, such as
pneumonia or AECOPD. Studies have shown that in the general popula-
tion, subjects with respiratory tract infections are more likely to experi-
ence a myocardial infarction within 2 weeks of infection (Meier, Jick,
Derby, Vasilakis, & Jick, 1998; Corrales-Medina, Madjid, & Musher,
2010). A retrospective review examining 24 h mortality following
AECOPD hospitalisation found that approximately 60% of deaths that
occurred resulted from cardiovascular causes (Pastor et al., 2013).
3.1.3. Pulmonary hypertension, hypertrophy and heart failure
There are two principal pathological features in the pulmonary vas-
culature common to most forms of pulmonary hypertension: excessive
vasoconstriction and remodelling of the pulmonary arteriolar wall,
which primarily occur by a mechanism of smooth muscle proliferation
within the medial layer (Demarco, Whaley-Connell, Sowers, Habibi, &
Dellsperger, 2010). Because ROSmaypromote vasoconstriction, smooth
muscle cell proliferation, and vascular remodelling, oxidative stress like-
ly plays a critical role in many forms of pulmonary hypertension.
Multiple studies have shown that 25–70% of COPD patients have
pulmonary hypertension, depending on the deﬁnition used (Rasubala,
Yoshikawa, Nagata, Iijima, & Ohishi, 2003; Sekine et al., 2014). In addi-
tion to this, it is estimated that 25% of patients withmoderate-to-severe
COPD develop pulmonary hypertension within 6 years if they have no
hypertension at baseline (Zhai, Yu, Wei, Su, & Christiani, 2014). The
pathological changes implicated in the development of pulmonary hy-
pertension can also be seen in tissue samples of COPD patients who
do not have a diagnosis of pulmonary hypertension (Weitzenblum,
1984; Santos et al., 2002).A major feature of COPD is emphysema, contributing to airway ob-
struction. The destruction of alveolar walls and enlargement of air-
spaces results in a reduction in gas exchange (van der Toorn et al.,
2007). To compensate for this, blood pressure is increased to facilitate
more pulmonary blood ﬂow leading to pulmonary hypertension. This
results in increased work in the right heart and over time this increased
workload can lead to concentric hypertrophy of the right ventricle (RV)
(Neofytou, Tzortzaki, Chatziantoniou, & Siafakas, 2012). This can lead to
reduced ejection fraction, elevated end diastolic RV pressure, imped-
ance of the right heart and, if left unchecked, can lead to heart failure.
These changes can be detected in COPD patients, especially in end-
stage COPD patients, using transthoracic echocardiography, which al-
lows for the measurement of various parameters in the heart such as
systolic and diastolic wall thickness, and chamber size. Both pulmonary
hypertension and right heart failure are associated with an increase in
morbidity and mortality in COPD patients, independent of the decline
in lung function (Stone, Machan, Mazer, Casserly, & Klinger, 2011).
3.2. Oxidative stress in cardiovascular disease
The presence of oxidative stress in the form of increased ROS/RNS
formation (e.g., O2•−, ONOO−) has been observed both clinically and
in animal models of CVD (Schnabel & Blankenberg, 2007; Afanas'ev,
2011). Although implicated in CVD, the cause–effect relationship of ox-
idative stresswith any of the different cardiovascular diseases has yet to
be established. The increased generation of ROS due to impaired mito-
chondrial reduction ofmolecular oxygen, secretion of ROS by inﬂamma-
tory cells, endothelial dysfunction, auto-oxidation of catecholamines, as
well as exposure to radiation or air pollution can drive the oxidative
stress in cardiac and vascular myocytes (Dhalla, Temsah, & Netticadan,
2000). In addition to the increased oxidant production, depression in
the antioxidant reserve has also been implicated in CVD. These typically
phenolic antioxidants (e.g., vitamin E) act as a protective mechanism in
cardiac and vascular myocytes, and their reduced levels appear to be
due to both the saturation by excess ROS/RNS and/or changes in gene
expression. The harmful effects caused by ROS/RNS in cardiovascular
tissues are mainly due to ability of the oxidant species to drive changes
in subcellular organelles (e.g., mitochondria), reduce NO• bioavailabili-
ty, and induce intracellular Ca2+-overload (Dhalla et al., 2000).
3.2.1. Cardiovascular generation of
reactive oxygen species/reactive nitrogen species
As stated earlier, in addition to phagocytising cells, NOX-dependent
ROS-generation has been observed in numerous non-phagocytising
cells, though at a lower level. In the cardiovascular system these include
vascular smoothmuscle cells (VSMCs), endothelial cells, adventitial and
cardiac ﬁbroblasts and cardiomyocytes (Cave, Grieve, Johar, Zhang, &
Shah, 2005). Normally, these cells continuously generate low levels of
ROS even in the absence of external stimuli, and ROS derived from vas-
cular NOX act as second messengers in VSMC signalling. Over long pe-
riods of time, vascular NOX complexes only produce low levels of
O2•−, with much of it generated intracellularly where it participates in
cell signalling (compared to phagocyte O2•− which is generated extra-
cellularly) (Fisher, 2009). When stimulated however, there is a signiﬁ-
cant increase in NOX-driven ROS production by these cells. It is
important to recognize that both vascular and phagocytic NOX play an
important role in superoxide production as phagocytes can inﬁltrate
cardiovascular tissues and facilitate the functional and structural alter-
ations observed in CVD (Matoba & Egashira, 2011).
3.2.2. Oxidative stress in the pathogenesis of cardiovascular disease
Damage to the endothelium is the initiating step in CVD. This dam-
age can expose endothelial cells, along with the underlying cell layers,
to the deleterious effects of the inﬂammatory process, which can ulti-
mately lead to the formation of atherosclerotic lesions. Cellular oxida-
tive stress caused by excess ROS/RNS production is considered to be
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Stefanadis, 2009). Exogenous factors contributing to oxidative stress
such as smoking and comorbid diabetes also contribute to vascular ox-
idative stress and are strong risk factors for CVD (Fearon & Faux, 2009).
Cigarette smoke has been associated with the down-regulation of key
exogenous and endogenous antioxidants such as vitamin C (ascorbic
acid), carotene, Gpx and SOD (Tsuchiya et al., 2002; Agnihotri et al.,
2009). This can lead to dysfunction in endothelial cells, monocytes
and VSMCs as well as mitochondrial damage. In addition to this, DNA
damage can be caused by oxidised lipids and this may also contribute
to the dysfunction of endothelial cells, VSMCs, T lymphocytes and mac-
rophages (Madamanchi & Runge, 2007).
Oxidative stress has also been associated with the apoptosis or pro-
grammed cell death of cardio myocytes (Singal, Khaper, Palace, &
Kumar, 1998). The loss of myocytes via apoptosis has been observed
in the infarct regions of myocardium from patients that have suffered
from heart failure or a myocardial infarction (MI) (Krijnen et al.,
2002). Both in vitro studies and in vivo animal model studies found
that apoptosis occurs in response to cardiovascular complications,
such as MI, and chronic pressure overload (Fiorillo et al., 2005). The
common factor in all of these conditions is the generation of oxidative
stress and oxidative stress is known to play a role in the initiation of ap-
optosis (Nagata et al., 2003). Additionally, the apoptosis of myocytes is
inhibited by antioxidants such as vitamin E and SOD, implicating ROS/
RNS in the pathological pathways of CVD (Kumar, Lou, & Singal,
2002). Although studies have implicated a role for ROS/RNS in CVD re-
lated apoptosis, the exact contribution of oxidative stress in the loss of
myocardial function and heart failure remains to be established.
3.2.3. Nitric oxide in cardiovascular disease
The role of nitric oxide NO• in vascular homeostasis and signalling
has been well characterized. As stated earlier, NO• plays a pivotal role
in the maintenance of vascular tone and vasoreactivity. In contrast to
this distinct role in cell physiology, NO• can also contribute to CVD pa-
thology. Under certain conditions eNOS (the endothelial isoform of
the nitric oxide synthase) becomes uncoupled from a NO• to an O2-pro-
ducing state (Montezano & Touyz, 2012). The excess O2 produced can
react with NO• resulting in the formation of excessive ONOO−. This re-
action reduces the bioavailability of NO•, leading to cardiovascular dys-
function and reduced endothelial vasoregulatory capacity (Kolluru, Bir,
& Kevil, 2012). ONOO− has also been shown to promote the uncoupling
of eNOS, propagating the increased ONOO− formation and decreased
NO• bioavailability (Cassuto et al., 2014).
3.3. Current treatments and antioxidant therapies
The current treatments for comorbid CVD are the same treatments
used for CVD independent of COPD, such as β receptor blockers, ACE in-
hibitors, or angiotensin receptor blockers. However, the beneﬁt of these
drugs in COPDpatientswith CVD is conﬂicting. Some studies have found
that these treatmentsmay be detrimental for COPD patients, worsening
the pulmonary symptoms of the disease (Nojiri et al., 2014). However,
others have shown that when given to COPD patients with and without
comorbid COPD, these treatments have shown notable beneﬁts with
regards to airway symptoms (Huang et al., 2013). This may be due to
the fact that both ACE inhibitors and angiotensin receptor blockers
have displayed pleiotropic antioxidant effects in addition to their anti-
hypertensive effects (Munger, 2011). Thus, this presents a unique op-
portunity for dual action therapy using CVD-speciﬁc treatments and
antioxidants, and obviously warrants further research.
CVD and COPD also overlap with regards to their non-
pharmacological management. Cardiovascular modifying factors such
as physical activity and diet modiﬁcation are reported to decrease hos-
pital readmission for COPD (McLachlan, Hambly, Almsherqi, El Oakley,
&McGuire, 2006). The recognition of the importance of oxidative stress
in CVD has led to the fervent use of antioxidants in the treatment andprevention of the disease, however, the results of prospective, random-
ized clinical trials have been generally disappointing (Myung et al.,
2013; Ye, Li, & Yuan, 2013). In contradiction, studies have shown that
antioxidant therapy is beneﬁcial in non-comorbid hypertension, athero-
sclerosis, ischaemic heart disease, cardiomyopathies and congestive
heart failure (Dhalla et al., 2000). It should be noted that almost all an-
tioxidant clinical studies only explored the effectiveness of traditional
scavenging antioxidants such as vitamin E.
With regards to antioxidant treatments, the protective role of exer-
cise in preventing oxidative stress is noteworthy. Acutely, it is known
that exercise causes oxidative stress (Fisher-Wellman & Bloomer,
2009). However, exercise also leads to longer-term activation and en-
hanced synthesis of antioxidants and antioxidant enzymes (e.g., SOD,
Gpx-1), as well as decreasing oxidant production (Gonzalez, Marquina,
Rondon, Rodriguez-Malaver, & Reyes, 2008). This may explain the links
between prolonged exercise and the beneﬁcial effects to both COPD
and CVD patients, and highlights the potential beneﬁts of targeting oxi-
dative stress in comorbid CVD.
Overall, it appears that targeting oxidative stress with antioxidant
enzyme modifying treatments may have great potential in COPD and
comorbid CVD by providing beneﬁcial effects with regards to both the
pulmonary and cardiovascular aspects.
4. Skeletal muscle wasting
4.1. Skeletal muscle wasting overview
Skeletal muscle wasting, also referred to as cachexia or skeletalmus-
cle atrophy, occurs in approximately 20 to 40% of all COPD patients
(Schols et al., 1998; Congleton, 1999; Maltais et al., 2014). Muscle
wasting is characterized by a marked decrease in skeletal muscle
mass, an increase in proportion of type I muscle ﬁbres in the diaphragm
and type 2muscle ﬁbres in the periphery, and associatedwith low exer-
cise capacity and skeletal muscle weakness. Skeletal muscle wasting in
COPD is a strong predictor of mortality, independent of decline in lung
function (Schols et al., 1998; Marquis et al., 2002; Swallow et al.,
2007). Although present in a large population of patients, the preva-
lence of muscle wasting can only be approximated as there are no sim-
ple techniques to measure muscle mass. Knowing this, the actual
prevalence and extent of muscle wasting in the COPD population are
likely underestimated. This is because all the data is extrapolated from
body weight measurements and lean body mass, an index of muscle
mass, may be reduced despite the preservation of total body weight.
This is further supported by the fact that patients have a proportionally
greater reduction in thigh muscle cross-sectional area compared to re-
duction in bodyweight (Marquis et al., 2002). This indicates that a pref-
erential loss of muscle tissue exists in emaciated patients with COPD
(Kim et al., 2008).
Skeletal muscle wasting, although not a directly fatal condition, re-
duces health-related quality of life and decreases survivability for
COPD patients. The main feature of comorbid skeletal muscle wasting
is a reduction in fat free mass (FFM) and is associated with weaker pe-
ripheral muscles, impaired functional status, as well as poor health-
related quality of life (Debigare, Cote, & Maltais, 2001; Mathur, Brooks,
& Carvalho, 2014). In COPD, the reduction inmusclemass is proportion-
al to that of the reduction in strength indicating that the remaining con-
tractile apparatus may be functionally preserved. However, in patients
chronically treated with glucocorticosteroids, it is possible for the loss
of strength to be disproportional to the reduction in muscle mass.
Deteriorations in FFM have also been described following acute ex-
acerbations. These COPD patients also experience a reduction in exer-
cise capabilities, with skeletal muscle alterations contributing to
limitations in exercise in addition to pulmonary dysfunction (Wust &
Degens, 2007). It should be noted that the strength of the quadriceps
is a key determinant of exercise tolerance in COPD. This is explained
by the inﬂuence that muscle strength has on the perceived leg effort
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symptom in 40–45% of patients with COPD (Debigare & Maltais, 2008).
4.1.1. Mechanisms of skeletal muscle dysfunction
The pathophysiological interaction between COPD and alterations in
skeletalmuscle tissue is poorly understood and represents an important
gap in knowledge of the disease. Skeletal muscle wasting in COPD is
multifactorial in nature with several of these factors likely interacting.
Many factors (e.g., inﬂammation, oxidative stress, and poor nutrition)
can initiate or enhance alterations in skeletal muscle, such as change
in ﬁbre type phenotypic expression and regenerative defects in periph-
eral muscles of patients with COPD (Maltais et al., 2014). In this review,
multiple risk factors will be brieﬂy discussed along with a more in-
depth discussion regarding the role of oxidative stress and ROS.
4.1.1.1. Smoking. Cigarette smoking or exposure to other airborne irri-
tants is unlikely to be the primary mechanism involved in skeletal
muscle wasting in COPD, as seen in several studies where patients and
control subjects were matched for smoking history (Maltais et al.,
2014). Nevertheless, smoking does have some effect on muscle biology
and it may predispose patients to the development of skeletal muscle
dysfunction (De Paepe et al., 2008; Rinaldi et al., 2012). Smoking is
also associated with skeletal muscle weakness in otherwise healthy in-
dividuals (Seymour et al., 2010; Barreiro et al., 2011; vanden Borst et al.,
2011).
4.1.1.2. Disuse. Peripheral (or limb) muscle dysfunction in COPD has
been partly attributed to a reduction in physical activity, or
“deconditioning.” In general, the disuse of muscle can lead to many of
the features and alterations of skeletal muscle in COPD patients: muscle
weakness, muscle atrophy, loss of type I ﬁbres, decreased cross-
sectional area of muscle ﬁbres, reduced oxidative enzyme activity, re-
duced capillary-to-ﬁbre ratio, early lactate release, reduced rate of phos-
phocreatine synthesis after exercise and altered redox status (Booth &
Gollnick, 1983; Coyle, Martin, Bloomﬁeld, Lowry, & Holloszy, 1985;
Larsson & Ansved, 1985; Polkey & Moxham, 2006). In healthy adultsFig. 5. Regulation of muscle mass relies on various hypertrophy and atrophy signalling pathwa
processes resulting in enhancedmuscle degradation as a result of protein breakdown.Myostatin
and ROS can lead to the downstream activation of atrophagy-related genes (e.g., Atrogin-1, Mu
also been implicated in the activation of theubiquitin–proteasome (UbP) system. TheUbP system
to Maltais et al. (2014) for an exhaustive overview of the signalling pathways involved.these changes are fully reversible in response to training and increased
exercise; however, full recovery is unusual in COPD patients (Troosters,
Gosselink, & Decramer, 2000; Polkey & Moxham, 2006, 2011; Man,
Kemp, Moxham & Polkey, 2009).
4.1.1.3. Inﬂammation. A low body mass index (BMI) has been linked to
systemic inﬂammation in COPD patients. As seen in Fig. 5, inﬂammation
plays a key role in the activation of protein breakdown in skeletalmuscle.
Inﬂammation results in theproduction of key cytokines, such as IL-8, that
can generate an array of cellular responses. This includes the induction of
the ubiquitin proteasome (UbP) system through the transcriptional ac-
tivities of NF-κB and FOXOs, apoptosis, and macroautophagy, all of
which have been linked to the muscle atrophy (Kandarian & Jackman,
2006). In COPD patients, there is a lack of evidence with regards to in-
ﬂammation in skeletal muscle during stable disease (Gosker et al.,
2003; Montes de Oca et al., 2005); however, increased inﬂammation is
seen during periods of exacerbation (Spruit et al., 2003; Yende et al.,
2006). Because of this, the role of inﬂammation as the key event for the
development of skeletal muscle dysfunction in COPD is still widely
debated.
4.1.1.4. Hypoxia. In humans (Hoppeler et al., 1990) and animals
(Magalhaes et al., 2005) muscle mass decreases under hypoxic condi-
tions. COPD patients that have low arterial O2 and reduced O2 delivery
tend to have lower body mass than those with normal levels of arterial
O2 and sufﬁcient O2 delivery (Semenza, 2009). Hypoxia may be a factor
driving changes in limb muscle tissue as hypoxia can induce down-
stream effects leading to the activation of the UbP system and reduced
myogenesis (Caron, Theriault, Pare, Maltais, & Debigare, 2009).
4.2. Oxidative stress in skeletal muscle wasting
In addition to chronic inﬂammation, hypoxia, cigarette smoke, sepsis
and an increased cost of breathing cause the increased generation of ox-
idants in the lungs (e.g., H2O2, O2•−, MDA) (Rahman, 2005). It is sug-
gested that, in addition to inﬂammatory mediators, these oxidants canys. In skeletal muscle wasting, there is an imbalance between these anabolic and catabolic
(a negative regulator ofmusclemass) can inhibitmuscle growth. Inﬂammatorymediators
RF-1) resulting in enhanced protein degradation. Inﬂammation and oxidative stress have
is theprimarymechanismof theprotein catabolism inmammalian skeletalmuscle. Refer
69I. Bernardo et al. / Pharmacology & Therapeutics 155 (2015) 60–79spill into circulation, increasing the systemic oxidative stress burden of
COPD patients (Zeng et al., 2013). In in vivo models of skeletal muscle
wasting in COPD, increased oxidative stress has been observed
(Rinaldi et al., 2012). This increase in oxidative stress canmodifymuscle
proteins, reducing their integrity and enhancing their degradation
(Aiken, Kaake, Wang, & Huang, 2011). Direct exposure to oxidative
stress from environmentally-derived oxidants, or indirect exposure via
cellular-derived ROS due to inﬂammation, can induce proteolysis.
Acute bouts of physical exercise and acute exacerbations can also in-
crease the level of oxidative stress (Couillard et al., 2003; Karadag,
Karul, Cildag, Yilmaz, & Ozcan, 2008; Stanojkovic et al., 2011). It is sug-
gested that oxidative stress may acutely affect skeletal muscle function
by inhibiting the activity of the sodium/potassium pump, sarcoplasmic
reticulum function, myosin ATPase and mitochondrial respiration
(Wust &Degens, 2007). In addition to these acute effects, chronic oxida-
tive stress also contributes to muscle wasting and dysfunction in both
respiratory and peripheralmuscles. The increased presence of ROS asso-
ciated with COPD causes an increase in the expression of UbP compo-
nents leading to increased protein breakdown in skeletal muscle
(Fig. 6) (Maltais et al., 2014). There is evidence that COPD patients
with muscle wasting experience a more severe abnormal oxidative
stress response to submaximal and maximal exercises compared to
non-muscle-wasted patients with COPD (Van Helvoort et al., 2006). Al-
though most studies focus on the increased signalling of atrophy path-
ways as the major driving force of comorbid skeletal muscle wasting,
it should be noted that decreases in hypertrophy signalling may also
contribute greatly to thepathology of the disease. Further studies are re-
quired to determine the exact contribution of these various pathways to
the disease.
4.3. Current treatments and antioxidant therapies
There are currently no effective drug treatments for skeletal muscle
wasting in COPD. Pharmacological treatments that have been exploredFig. 6. Points of therapeutic intervention in COPD and its comorbidities. Oxidative stress indiscr
development of multiple diseases regardless of COPD diagnosis. Using novel antioxidant thera
generation of ROS and RNS with pharmacological compounds could reduce lung and systemic
the quality of life of patients, and increase their survival.include anabolic steroids, growth hormone, other growth anabolic com-
pounds and bioactive nutrients (e.g., ghrelin, creatine) and antioxidants.
Most of these treatments have only shown little to modest beneﬁts
when treating skeletal muscle wasting and weakness in COPD. As with
CVD, skeletal muscle wasting and COPD also overlap with regards to
their non-pharmacological management. Currently, the most potent
treatment for limb muscle dysfunction is exercise training, which is al-
ready a key component for the management of COPD (Maltais et al.,
2014). Some treatments such as lifestyle modiﬁcations (diet and exer-
cise) and anabolic steroids have shown improvement in patients; how-
ever, they do not reverse the progression of muscle loss and may only
increase muscle growth without substantial improvements in strength
or endurance (Casaburi et al., 2004; Hansen, Gualano, Bozinovski,
Vlahos, & Anderson, 2006). Therefore, new treatments are needed as
limiting muscle wasting in COPD will lead to improved quality of life
and increased survivability of patients. Because of its role in the patho-
genesis of comorbid skeletal muscle wasting, targeting oxidative stress
may be able to slow the progression or onset of the disease, giving pa-
tients an improved quality of life whilst managing their other symp-
toms. Furthermore, it has been reported that increasing antioxidant
potential can improve muscle performance whilst attenuating muscle
fatigue (Maltais et al., 2014). Further pre-clinical and clinical studies
are required to determine the effectiveness of targeting oxidative stress
in comorbid skeletal muscle wasting.
5. Lung cancer
5.1. Lung cancer overview
Lung cancer is one of the more fatal comorbidities of COPD. It is cur-
rently themost frequently diagnosed cancerworldwide and is the num-
ber one cause of cancer-related deaths in males (Jemal et al., 2011).
Lung cancer accounts for up to 13% of all cancer diagnoses worldwide,
accounting for more than one million deaths per year (Alberg &iminately damages a number of tissues and, as such, has been implicated in the onset and
pies it may be possible to treat COPD, AECOPD and comorbidities of COPD. Inhibiting the
inﬂammation, reduce the severity and progression of COPD and comorbidities, improve
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of developing lung cancer and due to the presence of comorbid lung
cancer, the survival rate of these COPD patients is drastically low
(Raviv, Hawkins, DeCamp, & Kalhan, 2011). It is estimated that up to
70% of lung cancer patients have co-existing COPD, and one study
found that the most common cause of death among patients with air-
ﬂow obstruction was lung cancer (Lung Health Study Research, 2000).
It is also known that, whilst lung cancer survival in the general popula-
tion is very low, COPD patients with comorbid lung cancer have an even
lower rate of survival. In one study, lung cancer patients without COPD
had a 26% 3 year survival after diagnosis versus 15% in lung cancer pa-
tients with COPD (Kiri, Soriano, Visick, & Fabbri, 2010).
5.1.1. Lung cancer and chronic obstructive pulmonary disease links
It is well established that exposure to airborne irritants, especially
those in cigarette smoke, induces both diseases. Cigarette smoke,
among other airborne irritants, is an independent risk factor of both
COPD and lung cancer with approximately 80% and 90% of cases associ-
ated with cigarette smoking respectively (Fathy, Hamed, Youssif,
Fawzy, & Ashour, 2014). Additionally, almost 1% of COPD patients de-
velop lung cancer yearly, whichmay be associated with genetic suscep-
tibility to particulates found in cigarette smoke (Sekine, Katsura, Koh,
Hiroshima, & Fujisawa, 2012). COPD is also considered to be a risk factor
for lung cancer independent of smoking status. It has also been sug-
gested that even a small reduction in airﬂow signiﬁcantly predicted
lung cancer (Wilson et al., 2008). The Multiple Risk Factor Intervention
Trial reported that a 10% reduction in lung functionwas associatedwith
an almost 3-times greater risk of lung cancer compared to patients
without airﬂow limitations, after adjusting for smoking (Shaten et al.,
1997). It also indicated that the lag time between smoking cessation
and the beneﬁcial effects on lung cancer development may be as long
as 20 years. A separate study found that the presence of COPD increases
the risk of lung cancer by up to 4.5-fold (Wang, 2013). This indicates
that COPD patients have a greater risk of developing lung cancer com-
pared to those with normal pulmonary function regardless of smoker
status. On the other hand, a study looking at the prevalence of COPD
in lung cancer patients, independent of age, sex, or smoking history, de-
termined that the prevalence of pre- or co-existing COPD in recently di-
agnosed lung cancer cases was six-times greater than in smokers
without lung cancer (Young et al., 2009). The study found that approx-
imately 50% of newly diagnosed lung cancer patients had COPD,where-
as this numberwas only 8% in otherwise healthy smokers. This suggests
that impaired lung function may be more important than age or
smoking history as a predictor of lung cancer.
Whilst the association between lung cancer and COPD has always
been of great interest, the details of their various molecular pathways
involved and their clinical correlates have only begun to be established.
Chronic inﬂammation is known to induce both COPD and lung cancer
by means of the release of inﬂammatory mediators and the excess
production of ROS/RNS (Lawless, O'Byrne, & Gray, 2009; Lee, Walser &
Dubinett, 2009; Bozinovski et al., 2015). Inﬂammatory mediators may
promote the growth of bronchoalveolar stem cells, activation of NF-κB
and signal transducer and activation of transcription 3 (STAT3), which
all play crucial roles in the development of lung cancer (Sekine et al.,
2012). Chronic inﬂammation leads to increased ROS production, and in-
creased oxidative stress has also been associated with the development
of lung cancer (Barreiro et al., 2013).
5.2. Oxidative stress in lung cancer
The primary association between oxidative stress and the develop-
ment of lung cancer is the oxidative modiﬁcations to DNA as a result of
ROS/RNS (Cooke et al., 2003; Paz-Elizur et al., 2003). Oxidative damage
to DNA by ROS and RNS has been implicated in carcinogenesis (Cooke
et al., 2003). As stated earlier it is known that oxidant-inducedDNAdam-
age also involves single- or double-stranded DNA breaks and DNA cross-links, DNAdamage inducing either arrest or inductionof transcription, in-
duction of signal transduction pathways, replication errors, and genomic
instability, all of which have been linked to carcinogenesis (Dawane &
Pandit, 2012). It should be noted that studies have found that excessive
amounts of NO• increase apoptosis in some tumour cells, whereas re-
duced amounts of NO• can increase the vascularity of the tumour and
protect the cells from apoptosis, particularly in lung cancer (Masri, 2010).
Due to the direct damage to DNA and the increased demand for DNA
repair as a result of oxidative stress, more DNA mutations may occur.
One of themost important oxidativemodiﬁcations to DNA is the adduct
of •OH on DNA nucleobases. The 8-hydroxy-2′-deoxyguanosine (8-
OHdG) and/or its tautomeric 8-oxo-7,8-dihydro-2′-deoxyguanosine
(8-oxodG) have been widely studied and proven important mutagenic
adducts to DNA and are therefore key biomarkers of oxidative stress in-
duced carcinogenesis (Valavanidis et al., 2009a,2009b). Mutations of 8-
oxodG involve a GC→AT transversion which can modify protein tran-
scription as stated earlier in the review. In addition to this, ROS and
RNS may initiate carcinogenesis by attacking DNA nucleobases causing
changes in oncogenes and tumour suppressor genes (Valavanidis,
Vlachogianni, Fiotakis, & Loridas, 2013). Studies found that •OHcan gen-
erate various DNA phenotypes with various metastatic potentials
(Malins, Polissar, & Gunselman, 1996; Valavanidis et al., 2013). It is sug-
gested that these different phenotypes likely contribute to the diverse
physiological properties and heterogeneity characteristic of metastatic
cell population (Malins et al., 1996).
In addition to direct damage to DNA, ROS and RNS can indirectly
damage DNA via oxidative modiﬁcations to lipids. This occurs when
ROS and/or RNS react with cellular membrane phospholipids generating
lipoperoxide radicals (LOO•) and toxic aldehydes (malondialdehyde,
MDA). This results inmembranepermeability andmicrocirculation alter-
ation and also causes the activation of nuclear factors leading to other
pro-inﬂammatory agents (Valavanidis et al., 2013). MDA is a naturally
occurring by-product of lipid peroxidation and is a known mutagenic
and carcinogenic compound. MDA reacts with DNA to formmultiple ad-
ductswithmutagenic potential (Marnett, 2000). Additionally, MDA itself
has also been shown to be carcinogenic (Marnett & Tuttle, 1980).
As with patients with COPD and comorbid lung cancer, patients
without co-existingCOPDalso experience an increase in systemic oxida-
tive stress and inﬂammation (Barreiro et al., 2013). These processes can
cause the activation of NF-κB,which has been associatedwith the devel-
opment of comorbid lung cancer (Chen, Li, Bai, & Lin, 2011). NF-κB acti-
vation and the subsequent actions of inﬂammatory-related genes may
play a central role in both COPD and lung cancer. Activation of NF-κB in-
creases the release of inﬂammatory mediators that can induce COPD,
whilst also inhibiting apoptosis, inducing proliferation and, accelerating
cancer development (Karin, 2009). The release of these inﬂammatory
mediators can activate STAT3 which is a transcription factor with vari-
ous physiological functions. Continuous activation of the STAT3 signal-
ling pathway can potentiate pulmonary inﬂammation and induce
adenocarcinoma formation in the lung (Takata et al., 2012). Clinically,
activation of STAT3 and its downstream genes serve as biomarkers of
COPD and lung cancer diagnosis and prognosis (Qu et al., 2009).
As stated previously, oxidative stress can stimulate the recruitment
of macrophages and neutrophils which release various cytokines and
chemokines. Released matrix metalloproteinases and ROS promote in-
ﬂammation, induce apoptosis, matrix degradation, and ineffective tis-
sue repair, resulting in enlarged airspaces (emphysema) (Belvisi &
Bottomley, 2003). Bronchoalveolar stem cells may attempt to repair
and replace damaged alveolar cells however, in an inﬂammatory envi-
ronment, they can enhance carcinogenesis (Sekine et al., 2012).
5.3. Current treatments and antioxidant therapies
Treatment for lung cancer, regardless of co-existing COPD, depends
on the type and severity of the cancer with the main treatments being
surgery, chemotherapy and radiotherapy in varying combinations
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pressive effects against oxidative stress in patients that respond well
to the treatment, compared to non-responders (Gupta et al., 2010).
This phenomenonmay be at least partially responsible for the improved
survival among responders.
As with COPD, the most effective lung cancer prevention measure is
smoking cessation. Because of the long lag time between smoke cessa-
tion and beneﬁcial effects with regards to lung cancer development,
new treatments for comorbid lung cancer should be primarily focused
on prevention and early detection. Early detection, prevention and in-
tervention are critical for both COPD and lung cancer as both diseases
have high mortality rates and incur severe economic burdens world-
wide. Due to the strong associations and interactions between lung can-
cer and COPD, novel therapies for the prevention of developing
comorbid lung cancer should focus on targeting pathways implicated
in both diseases. Inﬂammation and oxidative stress go hand-in-hand
in the onset and development of both of these diseases and are there-
fore key candidates for preventative therapy of comorbid COPD. More
research is required to determine the exact contribution of oxidative
stress to the pathology of lung cancer and the effectiveness of antioxi-
dant compounds in the disease.
6. Osteoporosis
6.1. Osteoporosis overview
Osteoporosis is a progressive, metabolic bone disease that is charac-
terized by a decrease in bonemass and density which leads to a deterio-
ration in bone strength and an increased risk of fracture (Kanis et al.,
2013). Patientswith osteoporosis experience reduced bonemineral den-
sity (BMD) and deterioration of bone microarchitecture (Kanis, 2002).
Additionally, patients experience alterations to the amount and variety
of proteins in bone as a result of the disease (Donoso, Pino, Seitz, Osses,
& Rodriguez, 2015). Osteoporosis presents no actual symptoms; howev-
er the major consequence of osteoporosis is the increased risk of bone
fractures as a result of the bone alterations. The key difference between
normal bone fractures and osteoporotic fractures is that osteoporotic
fractures occur in scenarios where healthy individuals would not nor-
mally break a bone. Therefore, these fractures are often regarded as fra-
gility fractures. Generally, these fragility fractures occur in the vertebral
column, ribs, hips and wrists (Adachi et al., 2003; Leslie et al., 2014).
As bone is a dynamic tissue, it continuously renews itself throughout
life and this is accomplished via bone remodelling. This process is car-
ried out by a functional and anatomic structure known as the basicmul-
ticellular unit. This structure requires the coordinated action of three
major types of bone cells: osteoclasts, osteoblasts and osteocytes
(Feng & McDonald, 2011). The interactions between these cells and
multiple molecular mediators, including hormones, growth factors,
and cytokines, drive the remodelling process (Mundy, 1993). Bone re-
modelling follows a time sequence that lasts approximately six months
in humans and during this process, osteoclasts eliminate old and/or
damaged bone which is then replaced by new bone formed by osteo-
blasts. Osteocytes are relatively inert cells, however, they are primarily
responsible for themolecular synthesis andmodiﬁcation, and transduc-
tion of signals (akin to the nervous system) necessary to sustain me-
chanical loads (Compton & Lee, 2014). In order to prevent signiﬁcant
alterations to bone mass and/or mechanical strength following after
each remodelling cycle, the process of bone formation and bone resorp-
tion is tightly regulated and maintained in healthy bone (Feng &
McDonald, 2011). Any disturbance in the remodelling process can lead
to the development of metabolic bone diseases. Oxidative stress is
known to affect the remodelling process by altering the functions of
both osteoclasts and osteoblasts and, as such, is associated with the
pathogenesis of osteoporosis. Due to the overlap in risk factors of
COPD and osteoporosis, patients with COPD have an increased inci-
dence of osteoporosis (Jorgensen et al., 2007).6.1.1. Osteoporosis and chronic obstructive pulmonary disease links
In COPD, patient health and treatment is primarily focused on the
level of lung function and ability of oxygenation. Because of this, osteopo-
rosis often goes undiagnosed in COPD even though COPD patients are at
a higher risk of developing the disease. Osteoporosis, however,may be as
equally debilitating as COPD, and can further contribute to the impaired
respiratory function if the patient experiences vertebral compressions
and loss of height as a result of bone degradation (Silverman, 1992;
Yang et al., 2007; Masala et al., 2014). It is not clear why COPD patients
often develop osteoporosis, but many of the risk factors for osteoporosis
overlap with or are also associated with COPD. These risk factors include
smoking, chronic inactivity, reduced weight, medication taken, poor nu-
trition, low antioxidant status and oxidative stress (Cielen, Maes, &
Gayan-Ramirez, 2014). At amolecular level, the pathophysiology under-
lying the development of comorbid osteoporosis is largely unknown;
however, the risk factors and causes of the disease have been well
established.
Chronic treatment with glucocorticosteroids (GCS) is one of the
more obvious causes of osteoporosis in COPD patients (Canalis, 2005).
Although the use of GCS in the treatment of COPD is controversial due
to their limited effectiveness and major side effects, they are still pre-
scribed to patients with severe COPD and patients particularly prone
to exacerbations. Most studies conclude that a beneﬁcial effect from
GCS is only observed when administered to the most severely affected
patients with tendency to exacerbate (Falk, Minai, & Mosenifar, 2008;
Leuppi et al., 2013; Price, Yawn, Brusselle, & Rossi, 2013). The treatment
with GCS for airway impairment is associated with an increased occur-
rence of fractures (De Vries et al., 2007). The incidence of fractures, as a
result of osteoporosis, contributes to the overall disability andmortality
of patients with COPD, whilst adding to the economic burden of the
disease. The increased incidence of osteoporosis is also seen in patients
that are treated with GCs chronically due to other chronic diseases
(McDonough, Curtis, & Saag, 2008). Although GCS use is a risk factor
for the development of comorbid osteoporosis, it does not entirely ac-
count for the low bone mass and high prevalence of osteoporosis in
COPD patients. In addition to chronic GCS use, inﬂammation has also
been determined to be a major risk factor of comorbid osteoporosis.
Systemic inﬂammation as a consequence of COPD has been linked to
the development of a myriad of comorbidities, including osteoporosis.
One study showed that the increased arterial stiffness due to the sever-
ity of airway obstruction experienced by COPD patients is related to os-
teoporosis and various markers of systemic inﬂammation (Sabit et al.,
2007). One such inﬂammatory marker is interleukin (IL)-6; a cytokine
which may also contribute to the increased risk of other comorbidities.
In addition to its pro-inﬂammatory effects, IL-6 is involved in regulation
of bone turnover and has been implicated in osteoporosis development
(Ishimi et al., 1990). Another study suggested that COPD is associated
with increased insulin resistance (another metabolic disorder) and
that this is associatedwith elevation of the proinﬂammatorymarker tu-
mour necrosis factor (TNF)-α receptor expression (Hotamisligil, 1999;
Nieto-Vazquez et al., 2008). TNF-α is a documented stimulator of oste-
oclastic bone resorption andhas been implicated in postmenopausal os-
teoporosis (Boyce et al., 2005). In one study examining patients
awaiting pulmonary transplantation, of which 56% were COPD patients,
there was a positive correlation between TNF-α receptor expression
and bone turnover (Forli et al., 2008). Increased levels of the bone re-
sorption marker 1-CTP were proportional to increased levels of TNF-α
receptor II. This suggests a strong correlation between COPD induced in-
ﬂammation and increased bone loss.
As stated earlier, inﬂammation in COPD is also implicated in skeletal
muscle wasting leading to signiﬁcant reductions in FFM. The increased
enzyme catalytic activity in muscle wasting is also associated with
bone loss. Signiﬁcant changes in enzyme function, such as increased ac-
tivity of alkaline phosphatase (ALP), have been identiﬁed in sera collect-
ed from osteoporosis patients (Leung, Fung, Sher, Li, & Lee, 1993). These
changes have also been associated with increased bone metabolism,
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MMP activity (primarily MMP-9 and MMP-12), which is implicated in
parenchyma destruction, has also been linked to the development of os-
teoporosis in COPD patients (Bolton et al., 2009).
6.2. Oxidative stress in osteoporosis
In addition to inﬂammation, there have been a multitude of studies
implicating oxidative stress with an increased rate of bone loss, thus
making oxidative stress a risk factor for osteoporosis (Varanasi, Francis,
Berger, Papiha, & Datta, 1999; Chavan, More, Mulgund, Saxena, &
Sontakke, 2007; Stanojkovic et al., 2013; Cervellati et al., 2014). It is sug-
gested that ageing and the consequential increase in ROS are responsible
for bone loss (Almeida & O'Brien, 2013). Increased oxidative stress is as-
sociated with alterations in the activity and function of both osteoblast
and osteoclast cells; the two major bone cells involved in the pathogen-
esis of osteoporosis.
6.2.1. Osteoblasts
The role of oxidative stress in osteoblasts has only been researched
extensively in the past decade. As stated earlier, osteoblasts are respon-
sible for replacing old or damaged bone with new bone. Studies found
that osteoblasts can be induced to produce intracellular ROS (O2•−
and H2O2) and the production of which can cause a decrease in ALP
which can cause cell death, and this effect is partially inhibited by scav-
enging antioxidants (Darden, Ries, Wolf, Rodriguiz, & Key, 1996; Onyia
et al., 1999). In high concentrations, ROS can damage osteoblast cells,
preventing the normal growth and development of bone, and has
been shown to induce osteoblast cell death (Lee, Lim, Lee & Yang,
2006). Additionally, H2O2 can modulate the activity of intracellular cal-
cium in osteoblasts by increasing the amount of Ca2+ released from in-
tracellular Ca2+ stores (Nam, Jung, Yoo, Ahn, & Suh, 2002).
6.2.2. Osteoclasts
Whilst still notwell understood, the differentmechanisms and path-
ways involved in the differentiation of osteoclasts and their ability to re-
sorb bone are beginning to be elucidated. It is well known that ROS is
involved in this process, but the extent of its contribution is still to be
determined. Superoxide has been detected intracellularly in osteoclasts
and at the osteoclast–bone interface, suggesting a contribution from su-
peroxide in bone resorption (Key, Wolf, Gundberg, & Ries, 1994). It is
known that osteoclastic superoxide is produced by NOX (Darden et al.,
1996). H2O2 produced by endothelial cells associated with osteoclasts
and the H2O2 produced by osteoclasts have been shown to increase os-
teoclastic activity and bone resorption, which may contribute to the in-
creased breakdown of bone in osteoporosis (Bax et al., 1992). H2O2 has
also been implicated in various other osteoclast functions such as oste-
oclast motility, differentiation of osteoclast precursors and the regula-
tion of osteoclast formation (Steinbeck, Kim, Trudeau, Hauschka, &
Karnovsky, 1998). The reaction of H2O2 with tartrate-resistant acid
phosphatase found on the surface of osteoclasts is responsible for the
degradation of collagen and other proteins (Bull, Murray, Thomas,
Fraser, & Nelson, 2002). Additionally, antioxidants play a role in osteo-
clast activity. Osteoclasts innately possess the antioxidant enzyme
SOD in the plasma membrane (Steinbeck, Appel, Verhoeven, &
Karnovsky, 1994). Studies found that after treating osteoclast cells
with antioxidant enzymes such as SOD and catalase, ROS production is
inhibited indicating that antioxidant therapy may be beneﬁcial for pa-
tients with osteoporosis (Lee, Kim & Jang, 2014).
6.3. Current treatments and antioxidant therapies
In addition to diet supplementation with calcium and vitamin D,
there is also awide range of pharmaceuticals available for the treatment
of osteoporosis. The current anti-resorptive treatments prescribed to os-
teoporosis patients include a number of bisphosphonates which inhibitbone resorption (MacLean et al., 2008). These vary by way of adminis-
tration and are taken orally either daily, weekly, monthly or intermit-
tently. Many other drugs are available such as, but not limited to,
calcitonin and strontium renalate, both of which increase bone forma-
tion by stimulating osteoblasts, whilst reducing bone resorption via
inhibiting the activity of osteoclasts. Emerging research has shown ben-
eﬁcial effects of anabolic treatments in osteoporosis (Neer et al., 2001).
Currently, the only available pure anabolic drugs are parathyroid hor-
mone mimetics. The use of fully human monoclonal antibodies has
also been approved for osteoporosis and a number of drugs are being
tested clinically for osteoporotic treatment and prevention (Lewiecki,
2011; Padhi, Jang, Stouch, Fang, & Posvar, 2011). However, unsurpris-
ingly, there is a lack of interventional studies regarding the treatment
of osteoporosis in patients with COPD.
Antioxidant treatment for osteoporosis has proven to be quite effec-
tive. The beneﬁcial effects of antioxidants with regards to bone health
and osteoporosis have also been demonstrated epidemiologically and
through clinical intervention (Rao, 2013). Bearing in mind the possible
adverse effects of hormonal therapy and the increasing reports regard-
ing the side effects of bisphosphonates in the management of osteopo-
rosis, there is a high demand for complementary and/or alternative
medicine for the prevention and treatment of osteoporosis. This is espe-
cially true for COPD patients who are inherently at a greater risk of de-
veloping the disease. Due to the damaging effects of ROS on bone
growth and regulation, targeting oxidative stress in COPD patients
may prove to be beneﬁcial for both COPD and osteoporosis.
7. Novel antioxidant approaches for the
treatment of chronic obstructive pulmonary disease
Besides never smoking, smoke cessation is the only effectivemethod
for preventing the onset and progression of COPD. The progression
of airway inﬂammation, increased oxidative stress, and protease
burden even months/years after cessation, and non-responsiveness to
glucocorticosteroids have been documented as therapeutic challenges
for the treatment of COPD (Kalyanaraman, 2013). Because of this,
there is a lack of effective treatments for COPD and its comorbidities.
As stated throughout this review, tissue injury and inﬂammation as a
result of oxidative stress are common to COPD and many of its comor-
bidities. A common theme throughout this review is the similarity and
interplay between the pathological mechanisms of each condition and
it is this similarity that provides a unique therapeutic opportunity
(Fig. 6). Treatment with antioxidants may be able to progressively pre-
vent and treat multiple diseases by suppressing the generation of ROS/
RNS, neutralizing oxidants or both. Due to the overwhelming evidence
implicating oxidative stress in the pathogenesis of COPD and its comor-
bidities, it is only logical to consider antioxidant intervention in this
patient population. It is important that such interventions not only neu-
tralize the excessive ROS and RNS generated, inhibit peroxidation of
lipids, and the subsequent inﬂammatory response, but to also identify
the source of these oxidants and inhibit their generation (Selemidis
et al., 2008). Due to the imbalance in oxidants and antioxidants,
this can be achieved by two approaches: increasing the endogenous
antioxidant enzyme activity via enzyme modulators/mimetics, or by
replenishing the depleted non-enzymatic defences through dietary or
pharmacological means.
It should be noted that typical radical scavenging treatments, such as
vitamin E and other dietary antioxidants, have shown minimal im-
provements in either COPD or the comorbidities outlined in this review.
This may be due to the dose, route of administration or the speciﬁc an-
tioxidant given and thus more research is required to determine the
efﬁcacy of these compoundswith certainty. In addition, traditional anti-
oxidants act in a “sacriﬁcialmanner,” due to the fact that once they have
scavenged a radical, they are essentially consumed.
Undoubtedly, themost damaging of all the ROS/RNS are the hydrox-
yl radical and peroxynitrite. These species are extremely reactive and
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strate they come into contact with. Knowing this, the most effective
form of protection would be to prevent their generation in the ﬁrst
place and this cannot be performed by traditional antioxidants (scaven-
gers). Therefore, a pharmacological approach which inhibits the pro-
duction of oxidant species is required. In addition to this, it may also
prove beneﬁcial to use combination therapy and treat patients with
the pharmacological enzymatic antioxidants (e.g., NOX inhibitors)
whilst also supplementing themwith dietary antioxidants (e.g., vitamin
E supplements).
7.1. Novel antioxidants
As shown on the ROS cascade (Fig. 2), there are 3 key enzymes that
can be targeted in order to reduce oxidative stress; NOX, SOD, and Gpx/
Cat. These enzymes can either be inhibited to reduce their activity (e.g.,
NOX inhibitor— apocynin) or ampliﬁed/mimicked to increase their ac-
tivity (e.g., Gpx mimetics — ebselen). Outlined below are just some of
the enzymatic compounds that may be of therapeutic beneﬁt to COPD
patients (also see Table 1).
7.1.1. NADPH oxidase inhibitors
As stated earlier, NOX-1 and -2 are the primary generators of O2•−
and are responsible for the initiation of the ROS cascade (Fig. 2). NOX
is a unique target in the sense that inhibiting the activity of the enzyme
would not only reduce the generation of a single oxidant species but
also reduce the generation of all other ROS and RNS. Inhibiting NOX
would reduce O2•− production which would result in less available
O2•− for the generation of H2O2 and ONOO−, subsequently reducing
•OH generation and increasing •NO bioavailability as a result.
7.1.1.1. Current studies. There are several NOX inhibitors currently being
studied, however the most common is apocynin, which is a NOX inhib-
itor that preferentially blocks NOX-2 at low doses. It inhibits NOX
by preventing the assembly of the NOX enzyme subunits, resulting in
the reduced formation of NOX complexes (Selemidis et al., 2008;
Drummond et al., 2011). We have shown that apocynin reducesTable 1
Various antioxidant compounds that have been studied in the context of COPD and/or its
comorbidities. Pre-clinical and clinical tests are investigating, or have investigated, the ef-
fectiveness of intervention with various small-molecular weight antioxidant compounds
that target oxidant generation, or quench inﬂammation/cigarette smoke-derived oxidants
and aldehydes. Refer to Rahman andMacNee (2012) for an in-depth analysis of these var-
ious compounds.
Antioxidant compounds Examples
Thiol compounds N-acetyl-L-cysteine (NAC)
Glutathione esters
Fudosteine
Thioredoxin
Inducers of glutathione biosynthesis
Nrf2 activators CDDO-imidazolide
Sulforaphane
NOX, SOD, Gpx
Mimetics Salen compounds
Metaloporphyrins
Ebselen
Inhibitors Apocynin
Lipid peroxidation/protein carbonylation
inhibitors/blockers
Lazaroids/tirilazad
Edaravone
Other antioxidants/enzymes and oxidant
scavengers
Nitrone spin traps
Peroxynitrite decomposition catalysts
Porphyrins
Polyphenols, natural products, and dietary
agents
Polyphenols/ﬂavonoids/natural
compounds
(Apocynin, vitamin D, vitamin E,
omega-3-fatty acid)
Source of the data: Rahman and MacNee (2012).cigarette smoke-induced lung inﬂammation in mice (Bernardo et al.,
unpublished observations). Additionally, the inhibition of NOX-2 activ-
ity ameliorates inﬂuenza A virus-induced lung inﬂammation, indicating
that pharmacologically targeting NOX-2 may also have therapeutic po-
tential in seasonal and possibly pandemic inﬂuenza infection (Vlahos
et al., 2011; Vlahos, Stambas, & Selemidis, 2012). Because of this, the
possible therapeutic utility of NOX-2 inhibitors may extend to AECOPD.
Clinically, COPD patients treated with apocynin had reduced H2O2 and
NO2− in their exhaled breath concentrate compared to placebo control
(Stefanska et al., 2012).
7.1.2. Superoxide dismutase mimetics
There are 3 human isoforms of SOD (1, 2, and 3), each of which can
transform O2•− to H2O2. SOD3 (or extracellular SOD) is located in the
extracellular matrix, the junctions of airway epithelial cells, the surface
of airway smooth muscle, and the lining of blood vessels of the lung
(Kinnula & Crapo, 2003). It should be noted that smokers and COPD pa-
tients have increased sputum levels of SOD3 as an adaptive response to
the increased oxidative burden (Regan et al., 2011). Additionally, poly-
morphisms in the SOD3 gene have been associated with emphysema
but not COPD susceptibility (Sorheim et al., 2010). It is possible to en-
hance the conversion of O2•− to H2O2 by introducing SOD mimetics.
Thiswould result in the same effects caused by NOX inhibition: reduced
O2•−, increasedNO bioavailability, however, itwould also increase H2O2
generated. Although there is increased H2O2 generation, the newest
class of SOD mimetics (salen complexes — “salens”) have also shown
Catalase like activity, enhancing the neutralization of H2O2 in cells and
decomposing ONOO− (Sharpe, Ollosson, Stewart, & Clark, 2002). Addi-
tionally, it has been suggested that SODmimetics may be beneﬁcial for
the treatment of cancer in combination with traditional cancer thera-
pies (Thomas & Shariﬁ, 2012).
7.1.2.1. Current studies. Since the administration of exogenous SODs
themselves has often proven to be problematic, a variety of innovative
approaches are currently being explored, one of these being SOD mi-
metics. Multiple classes of SOD mimetics have been developed and
each class has generally been effective in animal models of COPD. Ad-
ministration of the SOD mimetic M40419 in rats treated with VEFG re-
ceptor blockers signiﬁcantly decreased markers of oxidative stress in
the lungs and prevented the development of emphysema (Tuder et al.,
2003). In cigarette smoke-exposed rats, treatmentwith the SODmimet-
ic AEOL 10150 was found to signiﬁcantly reduce BALF inﬂammation
(Smith et al., 2002). It is known that the acute loss of SOD3 in adult
mice causes death,whereas overexpression of SOD3 in animals exposed
to hyperoxia reduces mortality (Folz, Abushamaa, & Suliman, 1999;
Gongora et al., 2008). Additionally, administration of SOD mimetic sig-
niﬁcantly attenuated the elastase-induced emphysema in both wild-
type and SOD3 knockout mice (Yao et al., 2010). This study found that
SOD3 protected against oxidative fragmentation of extracellular matrix
(ECM), resulting in the mitigation of lung inﬂammatory response and
emphysema. Knowing this, it is possible that SOD3 may be more effec-
tive than other SOD isoforms for the management of COPD. Therefore,
the development of pharmacological mimetics to replenish and aug-
ment SOD3 in the lung may have a therapeutic potential for the treat-
ment of COPD/emphysema (Rahman, 2012).
7.1.3. Glutathione peroxidase mimetics
The Gpx family of enzymes, along with catalase, are responsible for
the termination of the ROS cascade. There are 8 known isoforms of
Gpx (1 to 8) but the most abundant isoform is Gpx-1, which is found
in the cytoplasm of almost all mammalian cells and whose preferred
substrate is H2O2 (Vlahos & Bozinovski, 2013). The main function of
Gpx is the reduction of H2O2 to H2O and O2; however, Gpx is also
known to reduce lipid peroxides to their corresponding alcohols. Addi-
tionally, it has been reported that Gpx-2 is a major cigarette smoke-
inducible isoform found in the lung (Singh et al., 2006). As with SOD,
74 I. Bernardo et al. / Pharmacology & Therapeutics 155 (2015) 60–79it is possible to increase the reduction of H2O2 by introducing Gpx (or
catalase) mimetics. This would result in the termination of the ROS cas-
cade by increasing conversion of H2O2 to H2O and O2, and subsequently
reduced levels of •OH and decreased levels of lipid peroxides.
7.1.3.1. Current studies. There is currently a limited amount of studies
exploring the effectiveness of Gpx mimetics in COPD. When exposed to
cigarette smoke, Gpx-1 knockout mice exhibited increased BALF neutro-
phils, macrophages, proteolytic burden, whole lung IL-17A, and MIP1
mRNA compared withWTmice (Duong et al., 2010). When treated pro-
phylactically with the Gpx-1 mimetic ebselen, the cigarette smoke-
induced increases in BALFmacrophages, neutrophils, proteolytic burden,
and macrophage and neutrophil chemotactic factor gene expression
were all inhibited in both theWTandknockoutmice. In addition, ebselen
inhibited established BALF inﬂammationwhen administered therapeuti-
cally, suggesting that Gpx-1 mimetics may have therapeutic utility in
inﬂammatory lung diseases where cigarette smoke plays a role such as
COPD (Vlahos & Bozinovski, 2013). In addition, we have shown that
ebselen caused a reduction in inﬂuenza A virus-induced lung inﬂamma-
tion in mice, suggesting that targeting Gpx-1 may be of therapeutic ben-
eﬁt for AECOPD (Yatmaz et al., 2013).
Ebselen has also been shown to be protective in vivo in disease situ-
ations hallmarked by oxidative stress such as diabetes-associated
atherosclerosis and cerebral ischaemia–reperfusion injury (Wong,
Bozinovski, Hertzog, Hickey, & Crack, 2008). Additionally, ebselen has
been used in clinical trials of acute ischaemic stroke and was found to
improve the outcome of patients when administered within 24 h of
stroke (Yamaguchi et al., 1998).
7.1.4. Nuclear factor erythroid 2-related factor 2 activators
In addition to the 3 enzymes in the ROS cascade, the DNA binding
protein nuclear factor erythroid 2-related factor 2 (Nrf2) presents a po-
tential target for reducing oxidative stress in COPD (Boutten, Goven,
Artaud-Macari, Boczkowski, & Bonay, 2011). Nrf2 is found in the cyto-
plasm of many mammalian cells and is responsible for the regulation
of various antioxidants and cytoprotective genes, acting as a “master
switch” for these genes. In response to oxidative stress, Nrf2 translocates
to the nucleus and binds to the antioxidant response element (ARE) of
target genes, along with other binding factors and cofactors, resulting
in the induction of stress response genes (Rahman, 2012). COPD patients
have decreased levels of Nrf2 in the lungs, and may be linked to the re-
duced antioxidant capacity observed in patients (Nguyen, Nioi, &
Pickett, 2009). In addition, Nrf2 may also help improve the clearance of
bacteria by alveolar macrophages, which is particularly relevant to the
prevention and treatment of AECOPD (Harvey et al., 2011).
7.1.4.1. Current studies. It is known that Nrf2 signalling is impaired in
several chronic diseases, including COPD, cancer, and neurodegenera-
tive diseases (Boutten et al., 2011; Bauer, Hill, & Alexander, 2013). The
levels of Nrf2 protein are decreased in lungs of patients with COPD
and one study found that Nrf2-dependent antioxidants was negatively
associated with severity of COPD, suggesting that therapy directed to-
wards enhancing Nrf2-regulated antioxidants may be a novel strategy
for attenuating the effects of oxidative stress in the pathogenesis of
COPD (Malhotra et al., 2008). Studies have shown increased susceptibil-
ity of Nrf2 knockoutmice to CS- or elastase-induced pulmonary emphy-
sema (Rangasamy et al., 2004; Iizuka et al., 2005; Ishii et al., 2005).
ComparedwithWT littermates, theNrf2 knockouts exhibitedmore pro-
nounced inﬂammation and neutrophilic elastase activity in the BALF,
enhanced alveolar expression of oxidative stress markers, increased
numbers of apoptotic endothelial and alveolar type II epithelial cells,
and decreased antioxidant and antiprotease gene expression in alveolar
macrophages. Nrf2 deﬁciency also results in impaired alveolar type II
cell growth and enhanced sensitivity to oxidants, thereby contributing
to abnormal lung injury and repair (Boutten et al., 2011). Treatment
with the Nrf2 activator CDDO-imidazolide was found to attenuatecigarette smoke-induced emphysema and cardiac dysfunction in mice
(Sussan et al., 2009). Nrf2 appears to protect against pulmonary
hyperoxia/bleomycin injury and ovalbumin challenge in mice, presum-
ably by upregulating the transcription of lung antioxidant defence en-
zymes. It was also found that treatment with Nrf2 activators may be
able to restore glucocorticosteroid sensitivity in COPD patients
(Malhotra et al., 2011). A clinical trial of theNrf2 activators sulforaphane
is currently in progress in patients with COPD (Barnes, 2013).
Activation of Nrf2 has also been observed to have anticancer effects.
Several studies have found that Nrf2-activating compounds can prevent
or suppress cancer in mouse models (Sporn & Liby, 2012).
8. Concluding remarks
COPD is amajor incurable global health burden and is the 4th largest
cause of death in the world. Exacerbations are a common occurrence in
COPD patients and contribute mainly to morbidity, death and health-
related quality of life. Comorbid diseases, in particular cardiovascular
disease and skeletal muscle wasting, are also common in COPD and po-
tentiate the morbidity of COPD, leading to increased hospitalisations,
mortality and healthcare costs. Current treatments have limited efﬁcacy
and fail to modify the factors that initiate and drive the long-term pro-
gression of COPD, its exacerbations and its co-morbidities. In addition,
no pharmacological treatment has been shown to reduce the risk of
death in COPD in prospective clinical trials. It is now evident that in-
creased oxidative stress within the local lung microenvironment is a
major driving mechanism in the pathophysiology of COPD and that it
may directly inﬂuence peripheral organ (e.g., heart, skeletal muscle,
brain, bone) behaviour in a ‘COPD-speciﬁcmanner’. Therefore, targeting
oxidant-dependentmechanisms that drive COPD and its co-morbidities
may have great therapeutic potential.
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